Point72 Asset Management L.P. purchased a new position in IGM Biosciences, Inc. (NASDAQ:IGMS – Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 27,246 shares of the company’s stock, valued at approximately $187,000.
Several other institutional investors also recently bought and sold shares of the stock. AQR Capital Management LLC purchased a new stake in shares of IGM Biosciences during the 2nd quarter worth approximately $84,000. Marshall Wace LLP increased its holdings in IGM Biosciences by 51.6% during the second quarter. Marshall Wace LLP now owns 107,267 shares of the company’s stock valued at $737,000 after buying an additional 36,491 shares during the period. XTX Topco Ltd lifted its stake in shares of IGM Biosciences by 70.9% during the 2nd quarter. XTX Topco Ltd now owns 20,408 shares of the company’s stock worth $140,000 after purchasing an additional 8,467 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of IGM Biosciences by 126.0% during the second quarter. Renaissance Technologies LLC now owns 108,693 shares of the company’s stock valued at $747,000 after buying an additional 60,593 shares during the last quarter. Finally, Bruce & Co. Inc. boosted its position in shares of IGM Biosciences by 53.8% in the 2nd quarter. Bruce & Co. Inc. now owns 100,000 shares of the company’s stock worth $687,000 after purchasing an additional 35,000 shares in the last quarter. 42.79% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other news, Director Julie Hambleton sold 15,132 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $14.00, for a total value of $211,848.00. Following the completion of the sale, the director now directly owns 2,000 shares of the company’s stock, valued at $28,000. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CEO Fred Schwarzer sold 3,946 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $11.54, for a total value of $45,536.84. Following the completion of the transaction, the chief executive officer now owns 250,124 shares in the company, valued at $2,886,430.96. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Julie Hambleton sold 15,132 shares of the stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $14.00, for a total transaction of $211,848.00. Following the completion of the sale, the director now directly owns 2,000 shares in the company, valued at approximately $28,000. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,034 shares of company stock worth $279,957. Company insiders own 57.00% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on IGM Biosciences
IGM Biosciences Stock Up 3.4 %
IGMS opened at $15.41 on Friday. The business’s 50 day moving average is $11.83 and its two-hundred day moving average is $9.85. IGM Biosciences, Inc. has a 52 week low of $3.81 and a 52 week high of $22.50. The firm has a market cap of $909.56 million, a price-to-earnings ratio of -3.58 and a beta of 0.21.
IGM Biosciences (NASDAQ:IGMS – Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.97). The firm had revenue of $1.25 million during the quarter, compared to analysts’ expectations of $51.75 million. IGM Biosciences had a negative net margin of 7,571.35% and a negative return on equity of 119.02%. Equities analysts expect that IGM Biosciences, Inc. will post -3.13 EPS for the current fiscal year.
IGM Biosciences Profile
IGM Biosciences, Inc, a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.
Featured Articles
- Five stocks we like better than IGM Biosciences
- What Makes a Stock a Good Dividend Stock?
- 3 Key Stocks to Ride China’s Stimulus-Driven Growth
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 3 Dividend Growth Stocks Set to Supercharge Your Portfolio
- P/E Ratio Calculation: How to Assess Stocks
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
Want to see what other hedge funds are holding IGMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IGM Biosciences, Inc. (NASDAQ:IGMS – Free Report).
Receive News & Ratings for IGM Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGM Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.